A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Virology Bookmark and Share

Virology

City of Hope’s Department of Virology strives to better understand the origin and development of herpes simplex virus and other herpes viruses, the biology of cytomegalovirus (a prime concern for HIV-infected and other immunocompromised patients such as transplant recipients), vaccine development and experimental therapies using gene transfer vectors such as adeno-associated virus (AAV) and lentivirus. Viral vectors have shown great promise in treating both cancers and HIV.

John A. Zaia, M.D., chair of the department, plays an integral role in the Hematopoietic Cell Transplantation Program’s efforts to understand the biology of cytomegalovirus (CMV)-related pneumonitis, which was a major limitation to the success of bone marrow transplantation, and later went on to develop the gene therapy program at City of Hope, focused on treatment of HIV with genetically modified stem cells and T cells.

The Department of Virology comprises more than 50 personnel, including professors, associate professors, support scientists, postdoctoral fellows, research associates, laboratory aides and administrative support.
 
Laboratory Research

John Zaia, M.D. – Antiviral Research
Zaia, department chair, joined City of Hope from Harvard in 1980. He directs two clinical research labs, the Cytomegalovirus (CMV) Lab and the HIV Lab, with interests in antiviral development in the area of herpes viruses and HIV. The CMV laboratory studies the immunobiology of CMV infection after hematopoietic cell transplantation (HCT) with emphasis on immune factors necessary for protection. The HIV laboratory focuses on developing new treatments for HIV/AIDS using optimal genetic vectors for anti-HIV gene transfer and novel drug therapy.

Edouard Cantin, Ph.D. – Neurovirology and Neuroimmunology
Cantin is director of the Laboratory of Neurovirology and Neuroimmunology. He investigates the role of the host immune response in the pathogenesis herpes simplex virus (HSV) infections in vivo, with particular emphasis on CNS infections and the regulation of latency. His laboratory is also investigating the mechanisms by which intravenous immunoglobulins (IVIG) act as a potent immunomodulatory drug to suppress virus induced hyper-inflammatory responses that in the CNS culminate in fatal encephalitis following infection with HSV or West Nile virus, or fatal pneumonia following infection with highly pathogenic influenza virus strains, such as pandemic H1N1. A long-term interest is to understand the genetic basis of innate resistance to HSV, as this may suggest rational approaches to controlling recurrent infections, and the development of serious diseases such as encephalitis.
 
Saswati Chatterjee, Ph.D. – Gene Therapy
Chatterjee directs the Adeno-Associated Virus (AAV) Laboratory and is interested in the biology of AAV vectors for therapeutic gene transfer. Her specific areas of interest include stem cell-based genetic therapies of acquired and inherited diseases, including HIV infection, cancer, cardiovascular and genetic diseases; virus discovery research in human stem cells and the study of genetic elements necessary for optimal gene-based therapies. She evaluates gene therapy approaches in both in vitro and in vivo pre-clinical models, with targeted progression toward clinical human gene therapy trials.

Jiing-Kuan Yee, Ph.D.Modeling human diseases with stem cells
Dr. Yee is interested in using cell reprogramming and gene editing to establish ex vivo human genetic disease models to explore the underlying disease mechanisms and develop therapeutic strategies for treatment.  He has established fibroblast-derived induced pluripotent stem cells (iPSCs) from spinal muscular atrophy and Wiskott-Aldrich syndrome patients.  He is studying the phenotypes of cells differentiated from these iPSC lines to understand the pathogenesis of the disease.  He is also using gene editing technology to modify the genome of the iPSCs to explore the possibility of treating these diseases with cell replacement therapy.
 
Experimental Therapeutics
The Department of Experimental Therapeutics was formed to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope and other cancer centers worldwide.

Virology

Virology

City of Hope’s Department of Virology strives to better understand the origin and development of herpes simplex virus and other herpes viruses, the biology of cytomegalovirus (a prime concern for HIV-infected and other immunocompromised patients such as transplant recipients), vaccine development and experimental therapies using gene transfer vectors such as adeno-associated virus (AAV) and lentivirus. Viral vectors have shown great promise in treating both cancers and HIV.

John A. Zaia, M.D., chair of the department, plays an integral role in the Hematopoietic Cell Transplantation Program’s efforts to understand the biology of cytomegalovirus (CMV)-related pneumonitis, which was a major limitation to the success of bone marrow transplantation, and later went on to develop the gene therapy program at City of Hope, focused on treatment of HIV with genetically modified stem cells and T cells.

The Department of Virology comprises more than 50 personnel, including professors, associate professors, support scientists, postdoctoral fellows, research associates, laboratory aides and administrative support.
 
Laboratory Research

John Zaia, M.D. – Antiviral Research
Zaia, department chair, joined City of Hope from Harvard in 1980. He directs two clinical research labs, the Cytomegalovirus (CMV) Lab and the HIV Lab, with interests in antiviral development in the area of herpes viruses and HIV. The CMV laboratory studies the immunobiology of CMV infection after hematopoietic cell transplantation (HCT) with emphasis on immune factors necessary for protection. The HIV laboratory focuses on developing new treatments for HIV/AIDS using optimal genetic vectors for anti-HIV gene transfer and novel drug therapy.

Edouard Cantin, Ph.D. – Neurovirology and Neuroimmunology
Cantin is director of the Laboratory of Neurovirology and Neuroimmunology. He investigates the role of the host immune response in the pathogenesis herpes simplex virus (HSV) infections in vivo, with particular emphasis on CNS infections and the regulation of latency. His laboratory is also investigating the mechanisms by which intravenous immunoglobulins (IVIG) act as a potent immunomodulatory drug to suppress virus induced hyper-inflammatory responses that in the CNS culminate in fatal encephalitis following infection with HSV or West Nile virus, or fatal pneumonia following infection with highly pathogenic influenza virus strains, such as pandemic H1N1. A long-term interest is to understand the genetic basis of innate resistance to HSV, as this may suggest rational approaches to controlling recurrent infections, and the development of serious diseases such as encephalitis.
 
Saswati Chatterjee, Ph.D. – Gene Therapy
Chatterjee directs the Adeno-Associated Virus (AAV) Laboratory and is interested in the biology of AAV vectors for therapeutic gene transfer. Her specific areas of interest include stem cell-based genetic therapies of acquired and inherited diseases, including HIV infection, cancer, cardiovascular and genetic diseases; virus discovery research in human stem cells and the study of genetic elements necessary for optimal gene-based therapies. She evaluates gene therapy approaches in both in vitro and in vivo pre-clinical models, with targeted progression toward clinical human gene therapy trials.

Jiing-Kuan Yee, Ph.D.Modeling human diseases with stem cells
Dr. Yee is interested in using cell reprogramming and gene editing to establish ex vivo human genetic disease models to explore the underlying disease mechanisms and develop therapeutic strategies for treatment.  He has established fibroblast-derived induced pluripotent stem cells (iPSCs) from spinal muscular atrophy and Wiskott-Aldrich syndrome patients.  He is studying the phenotypes of cells differentiated from these iPSC lines to understand the pathogenesis of the disease.  He is also using gene editing technology to modify the genome of the iPSCs to explore the possibility of treating these diseases with cell replacement therapy.
 
Experimental Therapeutics
The Department of Experimental Therapeutics was formed to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope and other cancer centers worldwide.
Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • The outlook and length of survival has not changed much in the past 25 years for patients suffering from an aggressive form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC). These patients still have few options for therapy; currently available therapies are generally toxic and do not incre...
  • “With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.” To meet this challenge, Chan and the urologic team at City of Hope [...
  • Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors. One of but a...
  • Brain cancer may be one of the most-frightening diagnoses people can receive, striking at the very center of who we are as individuals. Further, it often develops over time, causing no symptoms until it’s already advanced. Listen to City of Hope Radio as Behnam Badie, M.D., director of the Brain Tumor Pro...
  • The whole is greater than the sum of its parts. It takes a village. No man is an island. Choose your aphorism: It’s a simple truth that collaboration usually is better than isolation. That’s especially true when you’re trying to introduce healthful habits and deliver health care to people at risk of disease and...
  • When Maryland Governor Larry Hogan announced earlier this week that he has the most common form of non-Hodgkin lymphoma, he was giving voice to the experience of more than 71,000 Americans each year. The announcement came with Hogan’s promise to stay in office while undergoing aggressive treatment for the...
  • The spine can be affected by many different kinds of tumors. Malignant, or cancerous, tumors can arise within the spine itself. Secondary spinal tumors, which are actually much more common, begin as cancers in another part of the body, such as the breast and prostate, and then spread, or metastasize, to the spi...
  • Although most cancer occurs in older adults, the bulk of cancer research doesn’t focus on this vulnerable and fast-growing population. City of Hope and its Cancer and Aging Research Team aim to change that, and they’re getting a significant boost from Professional Practice Leader Peggy Burhenn, R.N....
  • Liz Graef-Larcher’s first brain tumor was discovered by accident six years ago. The then-48-year-old with a long history of sinus problems and headaches had been sent for an MRI, and the scan found a lesion in her brain called a meningioma – a tumor that arises in the meninges, the layers of tissue that cover a...
  • The colon and rectum are parts of the body’s gastrointestinal system, also called the digestive tract. After food is digested in the stomach and nutrients are absorbed in the small intestine, the remaining material moves down into the lower large intestine (colon) where water and nutrients are absorbed. The low...
  • If there is one truism about hospital stays it is that patients want to get out. For many, however, the joy of being discharged is tempered by the unexpected challenges that recovery in a new setting may pose. Even with professional help, the quality of care and treatment that patients receive at City of Hope [...
  • Jana Portnow, M.D., associate director of the Brain Tumor Program at City of Hope, didn’t expect to specialize in treating brain tumors. But, early in her career, she undertook a year of research on pain management and palliative care and, in that program, got to know many patients with brain tumors. After that...
  • Ask any patient: Nurses are as pivotal in their care as doctors. They answer the call of a patient in the middle of the night, they hold the patient’s hand as he or she takes on yet another round of treatment and, in the best-case scenario, they wave goodbye as the patient leaves the hospital, […]
  • Many oncologists, not to mention their patients, might think that there’s no place for mathematical analysis in the treatment of cancer. They might think that all treatment decisions are based on unique factors affecting individual patients, with no connection to other patients and their treatment regimen...
  • Within three days in 2007, Stephanie Hosford, then 37, learned that she was pregnant with her long-awaited second child – and that she had triple-negative breast cancer. Soon afterward, Hosford discovered that she and her husband, Grant, had been approved to adopt a little girl from China.  After encountering m...